Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
Donn Casale is recorded as CEO and Board Member at ARS Pharmaceuticals, Inc. (SPRY). ARS Pharmaceuticals, Inc. reported in an 8-K filed July 7, 2026 that Donn Casale was appointed Class III director, effective July 7, 2026. ARS Pharmaceuticals, Inc. reported in an 8-K filed July 7, 2026 that Donn Casale was appointed Chief Executive Officer, effective July 7, 2026. ARS Pharmaceuticals, Inc. reported in an 8-K filed May 13, 2026 that Donn Casale was appointed President, effective June 1, 2026. Donn Casale has spoken on 1 earnings call across 1 company, most recently for ARS Pharmaceuticals, Inc. on August 13, 2026.
“Mr. Casale was also concurrently appointed to the Board as a Class III director, to serve until the Company’s 2029 annual meeting of stockholders.”
“On July 7, 2026, the Board of Directors (the “Board”) of ARS Pharmaceuticals, Inc. (the “Company”) appointed the Company’s current President Donn Casale as the Company’s Chief Executive Officer, effective immediately, replacing Richard Lowenthal in such capacity.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Recorded current and former roles; source labels appear when available.
2026-07-07–present
2026-07-07–present
SEC 8-K
2026-06-01–present
Recorded roles and call appearances connecting this person to public companies.
CEO, Board Member
2026-06-01–present
Other people whose current roles at this company are on record from its filings.
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.
